A pharmaceutical company based in North America received EMA marketing approval for its bioequivalent product for an ultra-rare disease. However, because the originator product had been on the market for years previously without any competition, there was a great deal of brand loyalty among the treating physicians. As such, this company needed help marketing its product as a viable alternative treatment option and securing exclusive supply chains in individual EU countries.
The company partnered with WEP Clinical to take advantage of our experience gaining product sales in EU countries. Our country managers have local-language speaking capabilities and experience working in industry in their respective countries. This allows these managers to expertly handle all aspects of commercialization on behalf of the company, from registering the product with the country-specific health agencies, winning local tenders, negotiating reimbursement, providing QP services, and distributing product.